Mon, 19 Oct 2015 13:00:00 GMT ~ MEI Pharma to Present at 14th Annual BIO Investor Forum
[PR Newswire] - SAN DIEGO, Oct. 19, 2015 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that David Urso, JD, Senior Vice President, Corporate Development & General Counsel, will present at the 14th Annual Biotechnology Industry Organization (BIO) Investor Forum on Wednesday, October 21, 2015 at 9:00 a.m. Pacific time from the Parc 55 San Francisco. MEI Pharma, Inc. (MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer.
Tue, 06 Oct 2015 13:00:00 GMT ~ MEI Pharma Announces Data from Phase II Clinical Studies of Pracinostat Accepted for Oral Presentation at American Society of Hematology Annual Meeting
[PR Newswire] - SAN DIEGO, Oct. 6, 2015 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that data from the Company's ...
Wed, 02 Sep 2015 12:30:00 GMT ~ MEI Pharma Reports Fiscal Year 2015 Results
[PR Newswire] - SAN DIEGO, Sept. 2, 2015 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced results for its fiscal year ended June 30, 2015. "Despite a challenging end to the fiscal year, I am quite pleased with how the Company is positioned entering fiscal year 2016," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of MEI Pharma. "While we were obviously disappointed with the top-line data from our randomized study of Pracinostat in front-line myelodysplastic syndrome (MDS), our subsequent findings from the study, combined with the continued maturation of data from our ongoing study in acute myeloid leukemia (AML) and discussions with our clinical advisors, suggest that Pracinostat, in combination with hypomethylating agents (HMA) or other drug candidates, may still play a meaningful role in the treatment of patients with advanced hematologic diseases.
Link: http://www.otcmarkets.com/stock/MEIP/company-info Ticker: $MEIP OTC Market Place: Not Available CIK code: 0001262104 Company name: MEI Pharma, Inc. Company website: http://www.marshalledwardsinc.com Incorporated In: DE, USA
Market Value: Not Available Shares Outstanding: 34,155,997 a/o May 05, 2015 Float: Not Available Authorized Shares: Not Available Par Value: Not Available
$MEIP extra dd links
Company name: MEI Pharma, Inc. Company website: http://www.marshalledwardsinc.com